By XING YI in Shanghai | chinadaily.com.cn |
Original link: https://www.chinadaily.com.cn/a/202108/20/WS611f198ca310efa1bd66a0ea.html
The spillover effect of the China International Import Expo (CIIE) has accelerated the approval process of foreign new drugs and therapies in the country, according to Japanese pharmaceutical company Takeda.
The company first participated in the CIIE in 2018 with a 300-square-meter booth. It doubled the exhibition area in 2020 after it acquired Shire, a drug maker specialized in rare diseases treatment.
The company said that its five new products related to rare diseases, such as Fabry disease, haemophilia, Gaucher disease and hereditary angioedema, that it launched at the CIIE last year were approved by Chinese authorities this April.
Furthermore, three new molecular entity drugs were recognized by the Center for Drug Evaluation of the National Medical Products Administration as "breakthrough therapeutic variety" three months after their exhibition at the expo last year.
According to Takeda's five-year China development plan, the company is looking to introduce more than 15 innovative drugs to the Chinese market by 2025.
Shan Guohong, president of Takeda China, said, "We continue to be optimistic about the Chinese pharmaceutical market, and we are willing to work with parties at different levels of the government to advance China's healthcare system."
